Takeda to Acquire NDI-034858 From Nimbus Therapeutics for Up to $6 Billion

Cleary Gottlieb is representing Takeda, which announced on December 13, 2022, that it will acquire NDI-034858 from Nimbus Therapeutics.

Under the terms of the agreement, Takeda will pay Nimbus Therapeutics $4 billion upfront, and sales-based milestone payments up to $2 billion. The transaction is expected to be finalized in the first half of 2023. Closing of the transaction is subject to customary conditions, including completion of review under antitrust laws, including the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976.

NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases following successful recent Phase 2b results in psoriasis. When the transaction is complete, NDI-034858 will be known as TAK-279.

For more information, please see the press release here.